Value of internal limiting membrane peeling in surgery for idiopathic macular hole stage 2 and 3: a randomised clinical trial

U C Christensen
August 2009
British Journal of Ophthalmology;Aug2009, Vol. 93 Issue 8, p1005
Academic Journal
AIM: To determine the effect of internal limiting membrane (ILM) peeling on anatomical and functional success rates in stage 2 and 3 idiopathic macular hole surgery (MHS). METHODS: Randomised clinical trial of stage 2 and 3 idiopathic macular hole without visible epiretinal fibrosis and with less than 1 year’s duration of symptoms. Eyes were randomised to (1) vitrectomy alone without retinal surface manipulation, (2) vitrectomy plus 0.05% isotonic Indocyanine Green (ICG)-assisted ILM peeling or (3) vitrectomy plus 0.15% Trypan Blue (TB)-assisted ILM peeling. Main outcomes were hole closure after 3 and 12 months and best-corrected visual acuity after 12 months. RESULTS: 78 eyes were enrolled. Primary closure rates were significantly higher with ILM peeling than without peeling for both stage 2 holes (ICG peeling 100%, non-peeling 55%, p = 0.014) and for stage 3 holes (ICG peeling 91%, TB peeling 89%, non-peeling 36%, p<0.001). Visual outcomes in eyes with primary hole closure were not significantly different between the groups. CONCLUSIONS: Dye-assisted ILM peeling was associated with significantly higher closure rates than non-peeling in both stage 2 and 3 MHS. Intraoperative ILM staining with 0.05% isotonic ICG was not associated with a significantly different visual outcome than non-peeling or TB peeling in eyes with primary hole closure. TRIAL REGISTRATION NUMBER: NCT00302328.


Related Articles

  • Brilliant blue G-assisted peeling of the internal limiting membrane in macular hole surgery. Naithani, Prashant; Vashisht, Naginder; Khanduja, Sumeet; Sinha, Subijay; Garg, Satpal // Indian Journal of Ophthalmology;Mar2011, Vol. 59 Issue 2, p158 

    Dye-assisted internal limiting membrane (ILM) peeling and gas tamponade is the surgery of choice for idiopathic macular holes. Indocyanine green and trypan blue have been extensively used to stain the ILM. However, the retinal toxicity of indocyanine green and non-uniform staining with trypan...

  • Mascular Translocation May Offer a New AMD Option. Regillo, Carl; Cunningham Jr., Emmett T.; Solomon, Sharon D.; Pieramici, Dante J. // Review of Ophthalmology;Feb2001, Vol. 8 Issue 2, p63 

    Focuses on the use of a surgical approach called macular translocation in stabilizing visual outcome in patients with subfoveal choroidal neovascularization from age-related macular degeneration. Characteristics of an ideal patient for the surgery; Preoperative considerations for the surgery;...

  • Yırtıklı Retina Dekolmanlarında Maküler Dekolman Süresinin Tedavi Sonrası Erken Dönem Görme KeskinliÄŸine Etkisi. Kerimoğlu, Hürkan; Adam, Mehmet; Turan, Meydan; Öztürk, Banu; Pekel, Hamiyet; Okudan, Süleyman // Retina-Vitreus/Journal of Retina-Vitreous;Sep2009, Vol. 17 Issue 3, p202 

    Purpose: To evaluate the effect of the duration of macular detachment on best corrected visual acuity in eyes with rhegmatogenous retinal detachment treated with pneumatic retinopexy. Materials and Methods: The charts of patients with rhegmatogenous retinal detachment who had macular detachment...

  • Trial Results For Lucentis Show Promise for AMD.  // Review of Ophthalmology;Aug2005, Vol. 12 Issue 8, p6 

    Discusses the results of the Phase III Marina study which found that the investigational anti-vascular endothelial growth factors drug Lucentis show promise for age-related macular degeneration. Difference between the mean change in visual acuity from study entry between patients treated with...

  • Sight preserved in AMD patients receiving steroid derivative. Charters, Lynda // Ophthalmology Times;11/1/2003, Vol. 28 Issue 31, p59 

    Reports that findings from a phase II/III study conducted by the Anecortave Acetate Clinical Study Group indicate that anecortave acetate can have a positive impact on the treatment of patients with age-related macular degeneration (AMD). Long-term benefits that anecortave acetate can provide...

  • Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. Tufail, Adnan; Patel, Praveen J.; Egan, Catherine; Hykin, Philip; da Cruz, Lyndon; Gregor, Zdenek; Dowler, Jonathan; Majid, Mohammed A.; Bailey, Clare; Mohamed, Quresh; Johnston, Robert; Bunce, Catey; Wen Xing // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;6/26/2010, Vol. 340 Issue 7761, p1398 

    The article presents a prospective, double blinded, multicentre randomised controlled trial which examined the effectiveness of bevacizumab for treating neovascular age related macular degeneration. It was observed that patients in the bevacizumab group gained 15 or more letters of visual acuity...

  • Surgery Reverses Blindness. Doherty, Bridget; Harrar, Sari // Prevention;Jun2001, Vol. 53 Issue 6, p176 

    Discusses how macular translocation operations can improve vision in those with the wet form of age-related macular degeneration (AMD).

  • Feeder vessel therapy considered first-line for most cases. Guttman, Cheryl; Glaser, Bert // Ophthalmology Times;9/15/2001, Vol. 26 Issue 18, p52 

    Describes the feeder vessel therapy for wet age-related macular degeneration. Advantages of the technique; Comparison with other approaches; Principle behind the procedure.

  • AMD may need intervention in fifth decade. Charters, Lynda; Sternberg, Paul // Ophthalmology Times;02/01/2000, Vol. 25 Issue 3, p32 

    Focuses on the treatment of atrophic age-related macular degeneration. Information on the retinal disease; Biochemical basis for retinal pigment epithelium; Details on oxidant-induced apoptotic mechanism.


Read the Article

Other Topics